Trial Profile
A Multicenter, Open-label, Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv Squamous Cell Carcinoma of H&N (SCCHN) Who Failed Pembro Monotherapy or Experiencing SD Following Completion of 4 to 8 Cycles of Pembro Monotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biothera; HiberCell
- 12 Dec 2018 Status changed from recruiting to discontinued due to enrollment challenges resulting in changing treatment patterns. No patients remain on study.
- 06 Feb 2018 According to a Biothera media release, the patient treatment has commenced in this trial.
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.